This week, Jeremy talks to Dr. Paul Larkin, director of research at The ALS Association, and Dr. Frank Bennett, Chief Scientific Officer at Ionis and a pioneer in the field of antisense oligonucleotide research, about the FDA’s approval of tofersen and the future of ALS drug development.

To learn more about why the FDA’s decision on tofersen matters to everyone, check out: https://www.als.org/blog/tofersen-approved-sod1-als

For more information on antisense technology go to: https://www.als.org/research/research-we-fund/scientific-focus-areas/genetics/antisense-therapy-for-als

This episode is brought to you The ALS Association in partnership with CitizenRacecar.